An update on vaccination against group B streptococcus

References

• Schrag SJ, Zywicki S, Farley MM et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med.342(1), 15–20 (2000).
   PubMed Web of Science ®Google Scholar
• Skoff TH, Farley MM, Petit S et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin. Infect. Dis.49(1), 85–92 (2009).
   PubMed Web of Science ®Google Scholar
• Heath PT, Balfour G, Weisner AM et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet363(9405), 292–294 (2004).
   PubMed Web of Science ®Google Scholar
• Heath PT, Balfour GF, Tighe H, Verlander NQ, Lamagni TL, Efstratiou A. Group B streptococcal disease in infants: a case control study. Arch. Dis. Child.94(9), 674–680 (2009).
   PubMed Web of Science ®Google Scholar
• Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill. Summ.41(6), 25–32 (1992).
   PubMedGoogle Scholar
• Neto MT. Group B streptococcal disease in Portuguese infants younger than 90 days. Arch. Dis. Child. Fetal Neonatal Ed.93(2), F90–F93 (2008).
   PubMed Web of Science ®Google Scholar
• Kalliola S, Vuopio-Varkila J, Takala AK, Eskola J. Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. Pediatr. Infect. Dis. J.18(9), 806–810 (1999).
   PubMed Web of Science ®Google Scholar
• Fluegge K, Supper S, Siedler A, Berner R. Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany. Clin. Infect. Dis.40(5), 760–763 (2005).
   PubMed Web of Science ®Google Scholar
• Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatr. Infect. Dis. J.18(6), 524–528 (1999).
   PubMed Web of Science ®Google Scholar
• Lopez Sastre JB, Fernandez Colomer B, Coto Cotallo GD, Ramos Aparicio A. Trends in the epidemiology of neonatal sepsis of vertical transmission in the era of group B streptococcal prevention. Acta Paediatr.94(4), 451–457 (2005).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Radebe K, Crewe-Brown H et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann. Trop. Paediatr.23(1), 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• Berkley JA, Lowe BS, Mwangi I et al. Bacteremia among children admitted to a rural hospital in Kenya. N. Engl. J. Med.352(1), 39–47 (2005).
   PubMed Web of Science ®Google Scholar
• Gray KJ, Bennett SL, French N, Phiri AJ, Graham SM. Invasive group B streptococcal infection in infants, Malawi. Emerg. Infect. Dis.13(2), 223–229 (2007).
   PubMed Web of Science ®Google Scholar
• Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ323(7312), 533–536 (2001).
   PubMed Web of Science ®Google Scholar
• Moses LM, Heath PT, Wilkinson AR, Jeffery HE, Isaacs D. Early onset group B streptococcal neonatal infection in Oxford 1985–96. Arch. Dis. Child. Fetal Neonatal Ed.79(2), F148–F149 (1998).
   PubMed Web of Science ®Google Scholar
• Mifsud AJ, Efstratiou A, Charlett A, McCartney AC. Early-onset neonatal group B streptococcal infection in London: 1990–1999. BJOG111(9), 1006–1011 (2004).
   PubMed Web of Science ®Google Scholar
• Schuchat A. Group B streptococcus. Lancet353(9146), 51–56 (1999).
   PubMed Web of Science ®Google Scholar
• Phares CR, Lynfield R, Farley MM et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA299(17), 2056–2065 (2008).
   PubMed Web of Science ®Google Scholar
• Weisner AM, Johnson AP, Lamagni TL et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin. Infect. Dis.38(9), 1203–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Smaill F. Intrapartum antibiotics for group B streptococcal colonisation. Cochrane Database Syst. Rev. (2), CD000115 (2000).
   Google Scholar
• Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recomm. Rep.45(RR-7), 1–24 (1996).
   Google Scholar
• Vergnano S, Embleton N, Collinson A, Menson E, Russell AB, Heath P. Missed opportunities for preventing group B streptococcus infection. Arch. Dis. Child. Fetal Neonatal Ed.95(1), F72–F73 (2010).
   PubMed Web of Science ®Google Scholar
• Towers CV, Rumney PJ, Asrat T, Preslicka C, Ghamsary MG, Nageotte MP. The accuracy of late third-trimester antenatal screening for group B streptococcus in predicting colonization at delivery. Am. J. Perinatol.27(10), 785–790 (2010).
   PubMed Web of Science ®Google Scholar
• Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics115(5), 1240–1246 (2005).
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen N, Fanaroff AA et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N. Engl. J. Med.347(4), 240–247 (2002).
   PubMed Web of Science ®Google Scholar
• Jordan HT, Farley MM, Craig A et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr. Infect. Dis. J.27(12), 1057–1064 (2008).
   PubMed Web of Science ®Google Scholar
• Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA270(12), 1442–1448 (1993).
   PubMed Web of Science ®Google Scholar
• Colbourn T, Asseburg C, Bojke L et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost–effectiveness and expected value of information analyses. Health Technol. Assess.11(29), 1–226, III (2007).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med.294(14), 753–756 (1976).
   PubMed Web of Science ®Google Scholar
• Lin FY, Philips JB 3rd, Azimi PH et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J. Infect. Dis.184(8), 1022–1028 (2001).
   PubMed Web of Science ®Google Scholar
• Lin FY, Weisman LE, Azimi PH et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J. Infect. Dis.190(5), 928–934 (2004).
   PubMed Web of Science ®Google Scholar
• Maione D, Margarit I, Rinaudo CD et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science309(5731), 148–150 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng Q, Debol S, Lam H et al. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B streptococci from lungs of infected mice. Infect. Immun.70(11), 6409–6415 (2002).
   PubMed Web of Science ®Google Scholar
• Brodeur BR, Boyer M, Charlebois I et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect. Immun.68(10), 5610–5618 (2000).
   PubMed Web of Science ®Google Scholar
• Margarit I, Rinaudo CD, Galeotti CL et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J. Infect. Dis.199(1), 108–115 (2009).
   PubMed Web of Science ®Google Scholar
• Heath PT, Feldman RG. Vaccination against group B streptococcus. Expert Rev. Vaccines4(2), 207–218 (2005).
   PubMed Web of Science ®Google Scholar
• Lancefield RC. Two serological types of group B hemolytic streptococci with related, but not identical, type-specific substances. J. Exp. Med.67(1), 25–40 (1938).
   PubMedGoogle Scholar
• Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N. Engl. J. Med.319(18), 1180–1185 (1988).
   PubMed Web of Science ®Google Scholar
• Kasper DL, Paoletti LC, Wessels MR et al. Immune response to type III group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine. J. Clin. Invest.98(10), 2308–2314 (1996).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch. Dis. Child.88(5), 375–378 (2003).
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Kasper DL. Conjugate vaccines against group B Streptococcus types IV and VII. J. Infect. Dis.186(1), 123–126 (2002).
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Pinel J, Johnson KD, Reinap B, Ross RA, Kasper DL. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B streptococcus types VI and VIII. J. Infect. Dis.180(3), 892–895 (1999).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide–tetanus toxoid conjugate vaccine. Vaccine21(24), 3468–3472 (2003).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA et al. Use of capsular polysaccharide–tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J. Infect. Dis.182(4), 1129–1138 (2000).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Wessels MR et al. Safety and immunogenicity of capsular polysaccharide–tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis.179(1), 142–150 (1999).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose-response to type V group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine in healthy adults. Vaccine25(1), 55–63 (2007).
   PubMed Web of Science ®Google Scholar
• Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65–85 years old. J. Infect. Dis.190(3), 558–564 (2004).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J. Infect. Dis.188(1), 66–73 (2003).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J. Infect. Dis.189(6), 1103–1112 (2004).
   PubMed Web of Science ®Google Scholar
• Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen HK. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide–tetanus toxoid conjugate vaccines. J. Infect. Dis.185(9), 1277–1284 (2002).
   PubMed Web of Science ®Google Scholar
• Telford J. Design and development of novel vaccines for group B streptococci. In: Excellence in Paediatrics Conference. Acta Paediatrica, London, UK, 24 (2010).
   Google Scholar
• Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect. Immun.67(5), 2491–2496 (1999).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Fattom A, Basham L, Hawwari A, Harkonen S, Edelman R. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Vaccine14(5), 446–450 (1996).
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide–tetanus toxoid conjugate vaccine. Infect. Immun.62(8), 3236–3243 (1994).
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect. Immun.69(11), 6696–6701 (2001).
   PubMed Web of Science ®Google Scholar
• Lin FY, Weisman LE, Troendle J, Adams K. Prematurity is the major risk factor for late-onset group B streptococcus disease. J. Infect. Dis.188(2), 267–271 (2003).
   PubMed Web of Science ®Google Scholar
• Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr. Infect. Dis. J.22(6), 524–532 (2003).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197(5), 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez J, Levine OS, Sanchez J. et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J. Infect. Dis.182(5), 1553–1556 (2000).
   PubMed Web of Science ®Google Scholar
• Hillier S, Ferris D, Fine P et al. Women receiving group B streptococcus serotype III tetanus toxoid (GBS III–TT) vaccine have reduced vaginal and rectal acquisition of GBS type III. In: Infectious Diseases Society of America. USA, 186 (2009).
   Google Scholar
• Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum. Vaccin.4(6), 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Brent RL. Immunization of pregnant women: reproductive, medical and societal risks. Vaccine21(24), 3413–3421 (2003).
   PubMed Web of Science ®Google Scholar